Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Accumulated Expenses of $5.4 million for Q1 2026, down 84.83% year-over-year from $35.3 million in Q1 2025, and down 90.86% quarter-over-quarter from $58.6 million in Q4 2025.
Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 84.83% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 84.83% YoY), while the FY2025 annual figure was $58.6 million, down 84.31% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $5.4 million, down from $58.6 million in the prior quarter.
- The five-year high for Accumulated Expenses was $383.7 million in Q2 2022, with the low at $3.2 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $50.0 million (2024), against an average of $114.6 million.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 10759.65% in 2023, then slumped 93.9% in 2025.
- Sarepta Therapeutics' Accumulated Expenses stood at $5.0 million in 2022, then surged by 1488.62% to $78.7 million in 2023, then soared by 374.41% to $373.5 million in 2024, then slumped by 84.31% to $58.6 million in 2025, then plunged by 90.86% to $5.4 million in 2026.
- Business Quant data shows SRPT's Accumulated Expenses at $5.4 million in Q1 2026, $58.6 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 325.23 Mn |
| Mar 31, 2026 | 5.36 Mn |
| Dec 31, 2025 | 58.61 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 377.40 Mn |
| Mar 31, 2025 | 35.30 Mn |
| Dec 31, 2024 | 373.51 Mn |
| Sep 30, 2024 | 57.11 Mn |
| Jun 30, 2024 | 50.02 Mn |
| Mar 31, 2024 | 32.11 Mn |
| Dec 31, 2023 | 78.73 Mn |
| Sep 30, 2023 | 51.14 Mn |
| Jun 30, 2023 | 44.91 Mn |
| Mar 31, 2023 | 345.55 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 42.69 Mn |
| Jun 30, 2022 | 383.70 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 29.73 Mn |